Compare Hasbro, Inc. (HAS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Hasbro, Inc. trades at $96.1 (market cap $13.69B), while IDEXX Laboratories, Inc. trades at $570.81 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.4× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 2.89% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| HAS | IDXX | |
|---|---|---|
Market Cap | $13.69B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $766.68 |
52-Week Low | $70.95 | $526.44 |
Enterprise Value | $15.88B | $47.12B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $94.49, up 1.04% today, with strong technical and fundamental momentum. The stock exhibits a bullish trend, supported by consecutive earnings beats in Q4 2025, Q1 2026, and Q2 2026. Recent news highlights growth in adult-focused segments like Magic: The Gathering, with Q2 2026 revenue up 16% year-over-year. Valuation metrics show a P/E of 17.27 and P/S of 2.77, while analyst consensus is bullish with a $104.90 price target.
The outlook for Hasbro is positive, driven by IP strength and digital gaming growth, but risks include margin pressures from tariffs and high debt levels. Institutional buying and a 51.52% buy rating from analysts support upside potential, though investors should monitor execution risks and macroeconomic headwinds. The stock's current price is within 5% of its 52-week high, indicating strong near-term momentum.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
